AFFIMED NV (AFMD) Stock Price, Forecast & Analysis
USA - NASDAQ:AFMD - NL0015001ZQ0 - Common Stock
AFMD Key Statistics, Chart & Performance
The current stock price of AFMD is 0.1815 USD. In the past month the price decreased by -74.21%. In the past year, price decreased by -95.67%.
AFMD Latest News, Press Relases and Analysis
AFMD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.68 | 395.37B | ||
| AMGN | AMGEN INC | 15.34 | 180.64B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.95B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.59 | 109.44B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.86 | 70.87B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 889.65 | 59.47B | ||
| INSM | INSMED INC | N/A | 40.61B | ||
| NTRA | NATERA INC | N/A | 28.75B | ||
| BIIB | BIOGEN INC | 9.48 | 23.26B | ||
| INCY | INCYTE CORP | 16.82 | 21.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.44 | 20.82B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.09 | 14.55B |
Related stock screener links
About AFMD
Company Profile
Affimed NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of cancer immunotherapies. The company is headquartered in Heidelberg, Baden-Wuerttemberg and currently employs 76 full-time employees. The company went IPO on 2014-09-12. The firm's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The firm is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
Company Info
AFFIMED NV
Im Neuenheimer Feld 582
Heidelberg BADEN-WUERTTEMBERG 69120 DE
CEO: Adi Hoess
Employees: 76
Phone: 49621560030
AFFIMED NV / AFMD FAQ
What does AFMD do?
Affimed NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of cancer immunotherapies. The company is headquartered in Heidelberg, Baden-Wuerttemberg and currently employs 76 full-time employees. The company went IPO on 2014-09-12. The firm's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The firm is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
Can you provide the latest stock price for AFFIMED NV?
The current stock price of AFMD is 0.1815 USD. The price decreased by -34.95% in the last trading session.
Does AFFIMED NV pay dividends?
AFMD does not pay a dividend.
What is the ChartMill rating of AFFIMED NV stock?
AFMD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for AFMD stock?
10 analysts have analysed AFMD and the average price target is 12.24 USD. This implies a price increase of 6643.8% is expected in the next year compared to the current price of 0.1815.
Can you provide the PE ratio for AFMD stock?
AFFIMED NV (AFMD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.18).
Would investing in AFFIMED NV be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AFMD.
AFMD Technical Analysis
AFMD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AFMD. Both the profitability and financial health of AFMD have multiple concerns.
AFMD Financial Highlights
Over the last trailing twelve months AFMD reported a non-GAAP Earnings per Share(EPS) of -5.18. The EPS increased by 42.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -175.1% | ||
| ROE | -406.92% | ||
| Debt/Equity | 0.35 |
AFMD Forecast & Estimates
10 analysts have analysed AFMD and the average price target is 12.24 USD. This implies a price increase of 6643.8% is expected in the next year compared to the current price of 0.1815.
For the next year, analysts expect an EPS growth of 40.97% and a revenue growth -81.84% for AFMD